Keros Therapeutics (KROS) Assets Average (2020 - 2025)

Keros Therapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $540.4 million for Q4 2025.

• Quarterly Assets Average fell 9.57% year-over-year to $540.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $540.4 million (down 9.57% YoY) and the FY2025 annual result came in at $477.0 million, down 3.25% from the prior year.
• Assets Average was $540.4 million for Q4 2025 at Keros Therapeutics, down from $750.0 million in the prior quarter.
• Across five years, Assets Average topped out at $770.9 million in Q2 2025 and bottomed at $230.9 million in Q2 2022.
• A 5-year average of $408.4 million and a median of $346.9 million in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2021 — Assets Average soared 636.82% — and 2025, when it fell 9.57%.
• Keros Therapeutics' Assets Average stood at $242.6 million in 2021, then advanced by 15.28% to $279.7 million in 2022, then advanced by 24.48% to $348.1 million in 2023, then soared by 71.65% to $597.6 million in 2024, then slipped by 9.57% to $540.4 million in 2025.
• Business Quant data shows KROS's Assets Average at $540.4 million in Q4 2025, $750.0 million in Q3 2025, and $770.9 million in Q2 2025.